Magnetic resonance imaging bias field correction improves tumor prognostic evaluation after transcatheter arterial chemoembolization for liver cancer

Table 1 Analysis of general patient information, n (%)

Item	Statistic
Total number of patients, baseline	105
Age
< 65 years old	74 (70.48)
≥ 65 years old	31 (29.52)
Gender
Male	78 (74.29)
Female	27 (25.71)
Survival status at analysis
Alive	24 (22.86)
Deceased	81 (77.14)
Follow-up time (months)
Mean (range)	17.32 (0.21-142.55)
Median (interquartile range)	10.95 (4.23-21.32)
Etiology
Hepatitis B virus	89 (84.76)
Hepatitis C virus	9 (8.57)
Alcoholic liver disease	7 (6.66)
Cryptogenic liver cancer	1(0.95)
Cirrhosis	71 (67.62)
Barcelona Clinic Liver Cancer staging
B	31 (29.52)
C	71 (67.62)
D	3 (2.86)
Child-Pugh classification
A	70 (66.67)
B	34 (32.38)
C	1 (0.95)
ECOG performance status
0	58 (55.24)
1	41 (39.05)
2	4 (3.81)
3	2 (1.90)
Number of tumors
1	19 (18.10)
2	20 (19.05)
3	12 (11.43)
More than 4	54 (51.43)
Tumor size (cm)
Mean (range)	8.72 (1.6-19.8)
Median (interquartile range)	8.15 (5.2-11.8)
Portal vein invasion
Yes	44 (41.90)
No	61 (58.10)
Extrahepatic metastasis
Yes	9 (8.57)
No	96 (91.43)
TACE Type
Lipiodol	69 (65.71)
Drug-eluting beads	36 (34.29)
Number of TACE treatments
1	50 (47.62)
2	19 (18.10)
3	14 (13.33)
4 or more than 4	22 (20.95)

ECOG: Eastern Cooperative Oncology Group; TACE: Transcatheter arterial chemoembolization.